馬瑜婷，研究員，博士生導(dǎo)師，系統(tǒng)院執(zhí)行副院長。曾獲江蘇省自然科學(xué)一等獎(jiǎng)、中國青年女科學(xué)家獎(jiǎng)、鐘南山青年科技創(chuàng)新獎(jiǎng)、中國青年五四獎(jiǎng)?wù)?、全國先進(jìn)工作者、國務(wù)院政府特殊津貼等；入選中共二十大代表；入選國家萬人計(jì)劃領(lǐng)軍人才、國家海外高層次人才等；獲科技創(chuàng)新2030重大、國自然青B等項(xiàng)目資助。
     院校2015年引進(jìn)人才，曾在法國國家健康與醫(yī)學(xué)研究院、古斯塔夫魯西研究所、巴黎第五大學(xué)科德利埃研究中心完成博士后工作。

長期開展應(yīng)激重塑免疫景觀的研究，提出“多重應(yīng)激的免疫識別和調(diào)控”新理論，助力免疫治療新靶點(diǎn)和老藥新用策略的挖掘開發(fā)，承擔(dān)國家和省部級科研課題19項(xiàng)，在Nat Med、Nat Rev Immunol、Science等期刊發(fā)表論文60余篇，H指數(shù)40，入選全球前2%頂尖科學(xué)家，參編中英文專著5部，培養(yǎng)碩博士研究生20余名，擔(dān)任中國免疫學(xué)會(huì)理事、中國生物醫(yī)學(xué)工程學(xué)會(huì)常務(wù)理事等，是多個(gè)學(xué)術(shù)期刊資深副主編或編委。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1.Qin S#, Yang Y#, Wang H#, Li M#, Deng Y, Chen Y, Li C, Peng L, Xu L, Qiu X, Guan Y, Wang S, He Y, Wang X*, Ma Y*, Huang L*, Chen D*. scBrainScope: cross-species multidimensional brain atlas. Nucleic Acids Res. 2025 Nov 17:gkaf1092. (IF= 13.1)

2.Li P#, Liang M#, Zhu J#, Chen J#, Xia L, Jin Z, Zhang X, Zhang S, Wang Q, Liu Z, Ping Y, Wang Z, Wong CC, Zhang Y, Yang H, Ye Z, Ma Y*. Elevated activity of plasma dipeptidyl peptidase 4 upon stress can be targeted to reverse tumor immunosuppression. Pharmacol Res. 2025, 215:107696. (IF=10.5)

3.Ma Y#*, Kroemer G. The cancer-immune dialogue in the context of stress. Nat Rev Immunol. 2024, 24(4):264-281. (IF= 67.7)

4.Chen J#, Jin Z, Zhang S, Zhang X, Li P, Yang H, Ma Y*. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol Immunol 2023, 20(1):51-64. (IF= 21.8)

5.Ma Y#*. Tpt1 the balance toward immunosuppression upon cell death. Nat Immunol. 2021, 22(8):940-942. (IF= 27.8)

6.Yang H#, Xia L#, Chen J#, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, Fu L, Yang J, Pan Z, Yu K, He J, Morand E, Schlecht-Louf G, Krzysiek R, Zitvogel L, Kang B, Zhang Z, Leader A, Zhou P, Lanfumey L, Shi M, Kroemer G*, Ma Y*. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019, 25(9):1428-1441. (IF= 58.7, C100, F1000)

7.Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y*, Kroemer G*. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Cancer Res.2015, 15;75(18):3812-22. (IF= 9.088)

8.Vacchelli E#, Ma Y#, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L*, Kroemer G*. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015, 20;350(6263):972-8. (IF= 44.7, C100, F1000)

9.Ma Y#, Adjemian S#, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L*, Kroemer G*. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013, 18;38(4):729-41. (IF=21.884, ESI, C100)

10.Ma Y#, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G*, Zitvogel L*. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011, 208(3):491-503. (IF= 10.6, C100)